These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 30865026)

  • 1. An Ig Transmembrane Domain Motif Improves the Function of TCRs Transduced in Human T Cells: Implications for Immunotherapy.
    D'Apice L; Cuccaro F; Varriale S; Cipria D; Sartorius R; Circosta P; Cignetti A; Salerno M; Coscia MR; Oreste U; Marzullo VM; Martini G; Acuto O; De Berardinis P
    J Immunother; 2019 May; 42(4):97-109. PubMed ID: 30865026
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A TCR-based Chimeric Antigen Receptor.
    Walseng E; Köksal H; Sektioglu IM; Fåne A; Skorstad G; Kvalheim G; Gaudernack G; Inderberg EM; Wälchli S
    Sci Rep; 2017 Sep; 7(1):10713. PubMed ID: 28878363
    [TBL] [Abstract][Full Text] [Related]  

  • 3. γδTCR immunoglobulin constant region domain exchange in human αβTCRs improves TCR pairing without altering TCR gene-modified T cell function.
    Tao C; Shao H; Zhang W; Bo H; Wu F; Shen H; Huang S
    Mol Med Rep; 2017 Apr; 15(4):1555-1564. PubMed ID: 28259946
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Isolation and Characterization of an HLA-DRB1*04-Restricted HPV16-E7 T Cell Receptor for Cancer Immunotherapy.
    Mercier-Letondal P; Marton C; Deschamps M; Ferrand C; Vauchy C; Chenut C; Baguet A; Adotévi O; Borg C; Galaine J; Godet Y
    Hum Gene Ther; 2018 Oct; 29(10):1202-1212. PubMed ID: 30136612
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optimization of T-cell Reactivity by Exploiting TCR Chain Centricity for the Purpose of Safe and Effective Antitumor TCR Gene Therapy.
    Ochi T; Nakatsugawa M; Chamoto K; Tanaka S; Yamashita Y; Guo T; Fujiwara H; Yasukawa M; Butler MO; Hirano N
    Cancer Immunol Res; 2015 Sep; 3(9):1070-81. PubMed ID: 25943533
    [TBL] [Abstract][Full Text] [Related]  

  • 6. T cell receptor-based cancer immunotherapy: Emerging efficacy and pathways of resistance.
    Chandran SS; Klebanoff CA
    Immunol Rev; 2019 Jul; 290(1):127-147. PubMed ID: 31355495
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Framework engineering to produce dominant T cell receptors with enhanced antigen-specific function.
    Thomas S; Mohammed F; Reijmers RM; Woolston A; Stauss T; Kennedy A; Stirling D; Holler A; Green L; Jones D; Matthews KK; Price DA; Chain BM; Heemskerk MHM; Morris EC; Willcox BE; Stauss HJ
    Nat Commun; 2019 Oct; 10(1):4451. PubMed ID: 31575864
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chronic TCR-MHC (self)-interactions limit the functional potential of TCR affinity-increased CD8 T lymphocytes.
    Duong MN; Erdes E; Hebeisen M; Rufer N
    J Immunother Cancer; 2019 Nov; 7(1):284. PubMed ID: 31690351
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of genetically engineered CD4+ and CD8+ T cells expressing TCRs specific for a M. tuberculosis 38-kDa antigen.
    Luo W; Zhang XB; Huang YT; Hao PP; Jiang ZM; Wen Q; Zhou MQ; Jin Q; Ma L
    J Mol Med (Berl); 2011 Sep; 89(9):903-13. PubMed ID: 21556811
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influenza virus-specific TCR-transduced T cells as a model for adoptive immunotherapy.
    Berdien B; Reinhard H; Meyer S; Spöck S; Kröger N; Atanackovic D; Fehse B
    Hum Vaccin Immunother; 2013 Jun; 9(6):1205-16. PubMed ID: 23428899
    [TBL] [Abstract][Full Text] [Related]  

  • 11. RNA-transfection of γ/δ T cells with a chimeric antigen receptor or an α/β T-cell receptor: a safer alternative to genetically engineered α/β T cells for the immunotherapy of melanoma.
    Harrer DC; Simon B; Fujii SI; Shimizu K; Uslu U; Schuler G; Gerer KF; Hoyer S; Dörrie J; Schaft N
    BMC Cancer; 2017 Aug; 17(1):551. PubMed ID: 28818060
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular immunology lessons from therapeutic T-cell receptor gene transfer.
    Thomas S; Stauss HJ; Morris EC
    Immunology; 2010 Feb; 129(2):170-7. PubMed ID: 20561357
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel adoptive T-cell immunotherapy using a WT1-specific TCR vector encoding silencers for endogenous TCRs shows marked antileukemia reactivity and safety.
    Ochi T; Fujiwara H; Okamoto S; An J; Nagai K; Shirakata T; Mineno J; Kuzushima K; Shiku H; Yasukawa M
    Blood; 2011 Aug; 118(6):1495-503. PubMed ID: 21673345
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transgenic TCR expression: comparison of single chain with full-length receptor constructs for T-cell function.
    Zhang T; He X; Tsang TC; Harris DT
    Cancer Gene Ther; 2004 Jul; 11(7):487-96. PubMed ID: 15153936
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Minimal amino acid exchange in human TCR constant regions fosters improved function of TCR gene-modified T cells.
    Sommermeyer D; Uckert W
    J Immunol; 2010 Jun; 184(11):6223-31. PubMed ID: 20483785
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rapid re-expression of retrovirally introduced versus endogenous TCRs in engineered T cells after antigen-specific stimulation.
    van Loenen MM; Hagedoorn RS; de Boer R; van Egmond EH; Falkenburg JH; Heemskerk MH
    J Immunother; 2011 Mar; 34(2):165-74. PubMed ID: 21304404
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An optimized single chain TCR scaffold relying on the assembly with the native CD3-complex prevents residual mispairing with endogenous TCRs in human T-cells.
    Knies D; Klobuch S; Xue SA; Birtel M; Echchannaoui H; Yildiz O; Omokoko T; Guillaume P; Romero P; Stauss H; Sahin U; Herr W; Theobald M; Thomas S; Voss RH
    Oncotarget; 2016 Apr; 7(16):21199-221. PubMed ID: 27028870
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TCR-engineered T cells: a model of inducible TCR expression to dissect the interrelationship between two TCRs.
    Reuß S; Sebestyén Z; Heinz N; Loew R; Baum C; Debets R; Uckert W
    Eur J Immunol; 2014 Jan; 44(1):265-74. PubMed ID: 24114521
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improved expression and reactivity of transduced tumor-specific TCRs in human lymphocytes by specific silencing of endogenous TCR.
    Okamoto S; Mineno J; Ikeda H; Fujiwara H; Yasukawa M; Shiku H; Kato I
    Cancer Res; 2009 Dec; 69(23):9003-11. PubMed ID: 19903853
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Engineered TCR-T Cell Immunotherapy in Anticancer Precision Medicine: Pros and Cons.
    Zhao Q; Jiang Y; Xiang S; Kaboli PJ; Shen J; Zhao Y; Wu X; Du F; Li M; Cho CH; Li J; Wen Q; Liu T; Yi T; Xiao Z
    Front Immunol; 2021; 12():658753. PubMed ID: 33859650
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.